Objectives: Emergence of multidrug-resistant bacteria has encouraged vigorous efforts to develop antimicrobial agents with new mechanisms of action. In this study, the in vitro antibacterial activity of para-guanidinoethylcalix[4]arene was evaluated and compared with that of its constitutive monomer, para-guanidinoethylphenol. Hexamidine, a widely used antiseptic, and synthalin A, an old antidiabetic and anti-trypanosomal compound, were chosen as references.
Introduction
During the last three decades, a dramatic increase in nosocomial infections caused by multidrug-resistant bacteria has taken place. Recent studies reported that the prevalence of nosocomial infections caused by these microorganisms ranged from 4% to 10% in Europe. 1 Four bacterial species can be considered as the most frequent pathogens implicated in nosocomial infections: Escherichia coli (23%), Staphylococcus aureus (20%), Pseudomonas aeruginosa (11%) and Enterococcus spp. (6%). 2 The emergence of antibiotic-resistant bacteria has increased the complexity of anti-infective therapies being administered in hospitals. Coagulase-negative staphylococci, S. aureus and Enterococcus spp. are very often responsible for nosocomial infections and often encountered in the hospital environment. , in the USA, the National Nosocomial Infections Surveillance (NNIS) system report identified methicillin resistance in 59.5% of S. aureus infections in intensive care units (ICUs) . 3 This represented an increase of 11% in resistance when compared with rates for the period 1998 -2002 . From the European Antimicrobial Resistance Surveillance System (EARSS), data collected between 1999 and 2003 indicate that methicillin-resistant S. aureus (MRSA) accounted for 21% of infections due to S. aureus in Europe, but with large variation between countries, ranging from 1% in Northern Europe to 5% to 20% in Central Europe and 30% to 40% for Southern Europe and the UK. 1 For many years, vancomycin was the only effective treatment for serious MRSA infections. However, the latest NNIS report indicated that nearly 30% of all enterococci isolated from patients infected in ICUs are now resistant to vancomycin. 3 In Europe, the proportion of glycopeptide-resistant enterococci is still limited; according to the EARSS, 0.9% of Enterococcus faecalis and 9% of Enterococcus faecium isolates were resistant to vancomycin. 1 In the USA, the first four cases of vancomycin-intermediate S. aureus (VISA) were reported between 1997 and 1999; 4 and, more recently, strains fully resistant to vancomycin [vancomycin-resistant S. aureus (VRSA)] were isolated from three patients. 5 In the past few years, only four new agents with activity against MRSA and/or activity against vancomycin-resistant enterococci (VRE) have been introduced (quinupristin/dalfopristin, linezolid, daptomycin and tigecycline). However, the emergence of linezolid resistance in vancomycin-resistant E. faecium has been recently reported in Italy. 6 Gram-negative bacteria of the Enterobacteriaceae family are also important causes of nosocomial infections, especially urinary tract infections. According to the latest NNIS report, in 2003, 20.6% of all Klebsiella pneumoniae isolates from patients in ICUs, in the USA, were non-susceptible to third-generation cephalosporins.
3 This represented a 47% increase when compared with resistance rates during 1998-2002. Moreover, plasmidmediated quinolone resistance has been reported in K. pneumoniae and E. coli, associated with acquisition of the qnr gene. P. aeruginosa and Acinetobacter spp. are also a common cause of morbidity and mortality in hospitalized patients worldwide. According to the 2004 NNIS System report, the rate of resistance to third-generation/antipseudomonal cephalosporins, imipenem and quinolones increased by 20%, 15% and 9%, respectively, for P. aeruginosa strains isolated in 2003 when compared with isolates from 1998 to 2002. 3 Similar changes have been noted in European countries. 1 Thus, a growing number of bacteria are resistant to all or almost all of our currently available drugs. Given this situation, there is an urgent need to develop new antibacterial agents that target the broadest spectrum of bacteria. A new therapeutic agent with a new mechanism of action would be particularly attractive, because it could show less potential for crossresistance to currently prescribed agents. Among the various approaches that are under evaluation in our group is one dedicated to polycationic calixarene-based guanidinium podands that display an intrinsic antimicrobial activity. Calixarenes are oligomeric phenolic macrocycles, and it has been demonstrated that their excellent organizing behaviour into rigid structures gives them many functionalities. Very few reports, essentially only in the form of patents, have studied their antimicrobial properties; however, some calixarenes have shown interesting activities against bacteria, fungi, viruses and cancerous cells. 8 -12 Most experimental work has been carried out with Macrocyclon, since 1950. This compound enters macrophages by endocytosis and significantly affects the growth of Mycobacterium tuberculosis by disturbing lipid metabolism, with an inhibition of triglyceride lipase and phospholipases. 13 -15 In another approach, Ungaro et al. studied macrobicyclic peptido calixarenes that linked with the D-alanyl-D-alanine residue of the peptidoglycan and might act as vancomycin mimics. The compounds tested showed an anti-Gram-positive activity from moderate to good, although slightly inferior to vancomycin, and no activity was found against Gram-negative bacteria. 16, 17 On the basis of the fact that most bacteria are negatively charged, and focusing on the aforementioned organizing behaviour, the introduction of positive charges on the calixarene core leads to a constrained oligomeric polycation. As antimicrobial agents, the guanidinium derivatives have been modestly investigated in recent years. Most of the studied compounds are polyguanidinium species derived from the old, but non-commercial, anti-diabetic and anti-trypanosomal synthalin A. 18, 19 In our laboratory, we have observed a remarkable gain of antibacterial properties in the spatial organization of the monomeric paraguanidinoethylphenol into its tetrameric cyclic isomer. 20 The aim of this study was to confirm and expand the above findings by testing the activities of the para-guanidinoethylcalix [4] arene (compound 4, Figure 1 ) and its monomeric equivalent (compound 3, Figure 1 ), against five ATCC reference strains and five antibiotic-resistant Gram-positive and Gram-negative strains, containing different resistance determinants. Hexamidine (compound 1, Figure 1 ), a commonly used antiseptic solution, and synthalin A (compound 2, Figure 1 ) were chosen as references in this study, for their resemblance in terms of functional groups (guanidinium or amidine functions). Drugs were also tested for effect on viability by MTT assay, with determination of IC 50 , and for cytotoxicity by Neutral Red assay, with evaluation of CC 50 , in HaCaT and MRC-5 cell lines, in order to determine the selectivity index (SI).
Materials and methods
Bacterial strains E. coli ATCC 25922, S. aureus ATCC 25923 and ATCC 29213, E. faecalis ATCC 29212 and P. aeruginosa ATCC 27853 were used as reference strains, following guidelines of the CLSI (formerly NCCLS) 21 and of the Comité de l'Antibiogramme de la Société Française de Microbiologie (CA-SFM). 22 Five clinical isolates obtained from blood or rectal specimens were also tested in this study: penicillinase-producing E. coli (EcR1), methicillin-resistant S. aureus (mecA gene) (SaR1), vancomycin-resistant E. faecium (vanB gene) (EfR1), vancomycin-and teicoplanin-resistant E. faecalis (vanA gene) (EfR2) and P. aeruginosa overexpressing efflux pumps (PaR1). Isolates were selected on the basis of their resistant antimicrobial susceptibility testing profile [ Table S1 , available as Supplementary data at JAC Online (http://jac.oxfordjournals.org)]. Antimicrobial resistances were determined by the automated instrument VITEK2 (BioMerieux, France). Strains were grown on Mueller-Hinton agar (Difco, 225250) or in Mueller-Hinton broth (Difco, 275730).
Antimicrobial agents
Four drugs were tested: hexamidine (M ¼ 668.22 g/mol) (compound 1), synthalin A (M ¼ 498.45 g/mol) (compound 2), paraguanidinoethylphenol (M ¼ 293.24 g/mol) (compound 3) and para-guanidinoethylcalix [4] arene (M ¼ 1221.1 g/mol) (compound 4) (Figure 1 ). Compounds 3 and 4 were prepared as trifluoroacetate salts, as described previously. 20 Compound 2 was prepared as 3 and 4, starting from 1,6-diamino hexane. 
MIC determination
MICs were determined by broth microdilution method recommended by the CLSI. 21 For MIC determination, suspensions were prepared by suspending one isolate colony from Mueller -Hinton plates in 5 mL of Mueller -Hinton broth. After 24 h of growth, suspensions were diluted in distilled water to obtain a final inoculum of 5Â10 5 -5Â10 6 cfu/mL. Purity of isolates was checked throughout the study by examining the colony morphology and Gram staining. Two-fold serial dilutions of drugs were prepared in Mueller -Hinton broth in 96-well plates (Greiner, 650161), starting from a stock solution of 10 22 M. An equal volume of bacterial inoculum was added to each well on the microtitre plate containing 0.05 mL of the serial compound dilutions. After incubation for 18-24 h at 358C, MIC was determined with an ELISA reader (read at 540 nm; Multiskan EX, Thermo Electron Corporation, France) as the lowest concentration of compound whose absorbance was comparable with the negative control wells (broth only or broth with drug, without inoculum). Results are expressed as mean values of four independent determinations. Reference agents in clinical use were also tested in order to check susceptibility of strains: amoxicillin, ampicillin, oxacillin, penicillin G, ticarcillin and vancomycin.
MBC determination
The MBC was determined after the MIC assay. The MBC was obtained by subculturing the contents of each negative well and from the positive control (broth with inoculum, without drug) of MIC determination, onto substance-free Mueller -Hinton agar Petri dishes. The plates were incubated at 358C for 24 h. The MBC was taken as the lowest concentration of substance that results in more than 99.9% reduction of the initial inoculum. 23 Results are expressed as mean values of four independent determinations. If MBC is one or two dilutions above MIC, the drug is considered bactericidal. 24 
Cell lines and cell culture
HaCaT (human keratinocytes) 25 were kindly provided by Pierre Fabre Institut (Toulouse, France) and MRC-5 (human pulmonary embryonic fibroblasts) were obtained from BioMerieux (France). These cell lines were chosen as a model for the evaluation of antiseptics and/or antibiotics that could be used during acute skin infections, as previously proposed by some authors. 26, 27 The cells were maintained in Dulbecco's modified Eagle's medium (Invitrogen 61965) for HaCaT and in modified Eagle's medium (MEM; Invitrogen 41090) for MRC-5 supplemented with 10% decomplemented fetal bovine serum (Invitrogen 10270, lot 40Q5150K) without antibiotics at 378C, 5% CO 2 , under a humid atmosphere. HaCaT or MRC-5 were plated at 10 4 cells/well in 96-well plates (Sarstedt 831835). Forty-eight hours after plating, the growth medium was removed and replaced with the test solutions (100 mL). After 24, 48 and 168 h of exposure, viability and cytotoxicity tests were performed.
MTT assay
Viability tests were performed using a commercially available cell proliferation reagent MTT [3-(4,5-dimethylthiazolyl-2-yl)-2,5-diphenyltetrazolium bromide] (Sigma 1350380), as described previously. 28, 29 The assay is based on cleavage of the tetrazolium salt MTT by active mitochondria to produce an insoluble purple formazan salt. As this conversion only occurs with viable cells, it directly correlates with cell count. After 24, 48 and 168 h of exposure, 10 mL of a 5 mg/mL MTT solution was added to each well and plates were incubated at 378C for 4 h. Then, insoluble purple formazan was dissolved by adding 100 mL of SDS to each well. The absorbance A 540 was measured with a reference wavelength of A 690 , using an ELISA reader (Multiskan EX, Thermo Electron Corporation). The results were expressed as the per cent absorbance of treated versus untreated control cultures. Eight wells per dose and time point were counted in three different experiments.
Neutral Red assay
The cytotoxicity assay is based on the incorporation of the supravital dye, Neutral Red, into the lysosomes of viable cells after incubation with drugs. The amount of dye, after extraction from the lysosomes, is quantified spectrophotometrically and compared with Neutral Red recovered from untreated control cultures. The test was performed as described previously. 30 After 24, 48 and 168 h of exposure, the drug-containing medium from each well was replaced with 200 mL of MEM without phenol red (Invitrogen 51200) containing 50 mg/L Neutral Red for an additional 3 h incubation. Then, cultures were rinsed three times with PBS. Following removal of PBS, 200 mL of a solution of 1% acetic acid/50% ethanol was added to each well to extract the dye from lysosomes of viable cells. Absorbance was read at 540 nm using an ELISA reader (Multiskan EX, Thermo Electron Antibacterial activity of para-guanidinoethylcalix [4] arene Corporation). Eight wells per dose and time point were counted in three different experiments. Table 1 . Hexamidine 1 showed anti-Gram-positive as well as anti-Gram-negative activities, with weaker activity against P. aeruginosa. Synthalin A 2 was relatively poor against all strains tested. The monomer 3 was devoid of activity (MIC ! 512 mg/L for all strains), whereas para-guanidinoethylcalix [4] arene exhibited an antibacterial spectrum quite similar to hexamidine. MICs obtained for calixarene were 4 mg/L against E. coli, 8 mg/L against the two strains of S. aureus and 32 mg/L against P. aeruginosa and E. faecalis.
Results

MIC and MBC values are listed in
For clinical isolates (Table 1) , MICs obtained for hexamidine 1 and para-guanidinoethylcalix [4] arene 4 were similar to those obtained for reference strains (Table 1) , although one or two dilutions higher for some. However, differences observed were not considered significant. Thus, these two compounds showed a similar broad antibacterial spectrum, with activity extending to antibiotic-resistant bacteria. Synthalin A 2 and the monomer 3 remained inactive against these clinical isolates.
MBC has not been determined for monomer 3, because of high MIC values. MBCs obtained for hexamidine 1 and calixarene 4 were at least eight times higher than MICs (!64 mg/L for both compounds; Table 1 ). This suggests that they are bacteriostatic, for all strains tested.
Viability and cytotoxicity results are summarized in Table 2 . When the viability and the cytotoxicity assays are compared, the IC 50 and CC 50 values obtained are in accordance. The results from the two assays indicate that there are no differences between the two cell lines regarding their sensitivity to four compounds. The monomer 3 and the calixarene 4 showed no apparent cytotoxicity whatever the time of incubation (IC 50 . 256 mg/L after 24 h of exposure of HaCaT cells to both monomer 3 and calixarene 4). In contrast, loss of cell viability was seen after 24 h of exposure to hexamidine 1 (IC 50 ¼ 36.1 mg/L for HaCaT), and slightly lower concentrations were required for this effect after 48 and 168 h of incubation (IC 50 , respectively, 17.2 and 5 mg/L after 48 and 168 h for HaCaT). Synthalin A 2 also showed significant cytotoxicity, especially after 168 h of exposure (IC 50 , respectively, 97 and 1.2 mg/L after 24 and 168 h for HaCaT).
On the basis of the MIC and IC 50 values determined after 24 h of exposure, the SI (SI ¼ IC 50 /MIC) was calculated (Table 3) . SI values obtained with two assays (MTT and Neutral Red) were in good agreement. Very good SI values were obtained with the para-guanidino ethylcalix [4] arene 4 (SI ¼ 131 for E. coli, 66 for both S. aureus strains and 16 for P. aeruginosa), much higher than those obtained with monomer 3 (SI 2 for all strains), hexamidine 1 (SI values between 0.6 and 37) or synthalin A 2 (SI values between 0.1 and 15), our reference compounds.
Discussion
Antibiotic-and antiseptic-resistant bacteria are the major cause of nosocomial infections, with severe morbidity and mortality worldwide. This rising health and socioeconomic problem demands new measures for prevention and control. A number of new antibiotics have recently been approved by the FDA, such as tigecycline, the first compound of a new class of agents, the glycylcyclines, and daptomycin, a cyclic lipopeptide effective against MRSA.
23,31
The results presented here concern a new kind of polycationic synthetic compound displaying an intrinsic antibacterial activity. To the best of our knowledge, no reference antibiotic in Table 1 . MICs and MBCs (mg/L) obtained by broth microdilution method, according to CLSI and CA-SFM guidelines
clinical use, or under current investigation, carries a guanidinium function. Hexamidine, widely used in skin disinfection, and synthalin A, a non-commercial aliphatic bis guanidinium, were chosen here for their similarity in terms of functional groups, in order to obtain some preliminary structure -activity relationships. However, little data exist concerning the mechanism of action of hexamidine and contradictory information about its antibacterial spectrum is found in the literature. 32 It has also been suggested that the bactericidal activity of some commercial alcoholic solutions is attributable to synergy between ethanol and hexamidine. 32 In our study, we confirm, for hexamidine 1, a bacteriostatic activity extending to both Gram-positive and Gram-negative strains. Synthalin A 2 is devoid of antibacterial activity, so the guanidinium group alone seems not to be sufficient for antibacterial activity. Hexamidine 1 and the paraguanidinoethylcalix [4] arene 4 showed an interesting antibacterial activity: aromatic heterocycles, alkyl side chains and guanidinium groups, in the correct spatial orientation, could have a real importance in terms of antibacterial activity. We confirmed here the previously observed lack of antibacterial activity of monomeric para-guanidinoethylphenol 3 and the significant gain of activity with the spatial organization into its tetrameric cyclic isomer. 20 The presence of aromatic heterocycles and guanidinium groups is not sufficient to obtain an antibacterial activity; organization into a calixarene structure that closely tethers and arrays at its upper rim four guanidinium groups seem to be very important; it could result in a synergistic effect in ionic interactions with membrane targets. We are currently investigating membrane targets that may synergize the ionic effects reported here.
The para-guanidinoethylcalix [4] arene 4 appears as a very interesting compound: taken together, our results show that this drug is effective in inhibiting several Gram-positive and Gram-negative bacteria, without increasing toxicity on HaCaT and MRC-5 cell lines. Its broad antibacterial spectrum is similar to hexamidine 1. Interestingly, hexamidine 1 and synthalin A 2 show a higher time-dependent cytotoxicity.
MTT and Neutral Red assays used in this study are commonly employed for the detection of cytotoxicity or cell viability following exposure to various compounds. Only few antibiotics and antiseptics have been tested on human fibroblasts and keratinocytes. 26, 27 Considering a possible topical use, it appeared essential for us to test our compounds on these two cell lines. Synthalin A was considered as a cytotoxicity control because of its known toxicity on cells. 18 It has been previously reported that different cytotoxicity assays can give different results depending on the test agent used and the assay employed. 33, 34 In our study, the MTT assay appears to be equally sensitive as the Neutral Red assay in detecting early toxicity (after 24 h of exposure). However, two limitations should be noted: (i) MTT assay measures the activity of mitochondrial dehydrogenases that could be enhanced by some compounds; (ii) the Neutral Red assay seems to be more consistent with the cell line; results are more reproducible, absorbances are higher and standard deviations less significant when the test is performed on the HaCaT cell line. We therefore decided that the two assays should be used to determine cell viability (MTT assay) and cytotoxicity (Neutral Red assay) in in vitro studies, as this would increase the reliability of the results obtained.
As we demonstrated a significant antibacterial activity with the para-guanidinoethylcalix [4] arene 4, against our five reference strains, we attempted to determine whether its efficiency is conserved against antibiotic-resistant bacteria. Five clinical isolates were included in this study. These isolates were chosen because of the presence of only one phenotypically or genetically characterized resistance determinant. Resistance profiles are typical of resistant bacteria frequently isolated from nosocomial infections. 2 We showed that the calixarene derivative 4 retains its efficiency against antibiotic-resistant bacteria, such as MRSA or VRE. This means that the paraguanidinoethylcalix[4]arene 4 is not affected by the resistance mechanisms of these clinical isolates (such as b-lactamase, PBP2a or efflux pumps) and may represent an alternative agent or auxiliary to control important nosocomial pathogens. Timekill curve studies are currently under investigation to confirm and expand our understanding of the time-dependent or concentration-dependent nature of the various compounds.
These results make the para-guanidinoethylcalix [4] arene 4 potentially very valuable as a new agent or adjuvant for antimicrobial chemotherapy. A key to future developments is to clearly understand the mode of action of this antibacterial compound. Actually, several polycationic peptides isolated from animals, plants and bacterial species have been studied in terms of antimicrobial properties. 35 Some of these small, positively charged peptides possess a broad antibacterial spectrum, including antibiotic-resistant bacteria such as MRSA. Structureactivity relationship studies of these peptides reveal two main requirements for antimicrobial activity: (i) a cationic charge; and (ii) an induced amphipathic conformation. 36 Their mechanism of action has been most studied on Gram-negative bacteria; the initial association of peptides with the bacterial membrane occurs through electrostatic interactions between the cationic peptide and anionic lipopolysaccharide in the outer membrane leading to membrane perturbation. 36 Access to the cytoplasmic membrane is then possible through these destabilized areas. Different mechanisms lead to perturbation of the integrity of the cytoplasmic membrane or peptide translocation into the cytoplasm. Cationic peptides are thought to interact with DNA, RNA and/or cellular proteins and to inhibit synthesis of various compounds.
The para-guanidinoethylcalix [4] arene is a polycationic compound, and we could speculate that its mechanism of action should be close to that of polycationic peptides. Additional studies are required to determine its actual mode of action and to elucidate the relationship between calixarene structure and antibacterial activity. This requires the development of parent compounds and their non-conic conformers, as well as the linear oligomers. This is under current investigation. NR, Neutral Red. 1, hexamidine; 2, synthalin A; 3, para-guanidinoethylphenol; 4, para-guanidinoethylcalix [4] arene.
